E Fund Management Co. Ltd. Sells 7,226 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

E Fund Management Co. Ltd. trimmed its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 30.3% in the 4th quarter, Holdings Channel reports. The fund owned 16,612 shares of the biotechnology company’s stock after selling 7,226 shares during the quarter. E Fund Management Co. Ltd.’s holdings in BioCryst Pharmaceuticals were worth $125,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after purchasing an additional 127,708 shares during the period. Fisher Asset Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after buying an additional 481,359 shares during the last quarter. Two Sigma Advisers LP increased its position in BioCryst Pharmaceuticals by 13.6% during the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after buying an additional 261,500 shares in the last quarter. FMR LLC increased its position in BioCryst Pharmaceuticals by 2.4% during the 3rd quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock valued at $15,112,000 after buying an additional 46,110 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after buying an additional 91,998 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BCRX has been the subject of several analyst reports. Needham & Company LLC raised their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price on the stock. Evercore ISI raised their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.69 on Monday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The company has a market capitalization of $1.61 billion, a P/E ratio of -12.61 and a beta of 1.85. The company has a fifty day moving average of $8.15 and a 200 day moving average of $7.87.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the business posted $0.28 earnings per share. Analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.